Author Login

Correspondence to Author: Oanal T. Cilson, 

Oanal T. Cilson, Internal Medicine, St. George’s University School of Medicine| Morristown Medical Center, Morristown, New Jersey, USA.

Abstract : Blood transfusions are necessary for patients with sickle cell disease (SCD) and thalassemia as part of their supportive care. Red cell alloimmunization is one of the treatment’s most dangerous adverse effects, though. This study set out to determine the frequency and specificity of red cell alloimmunization in Egyptian individuals with sickle cell anemia and thalassemia. In this study, 200 Egyptian patients who had received several transfusions, 140 patients with transfusion-dependent thalassaemia, and 60 patients with sickle cell anemia who were receiving care at the Pediatric Children Hospital at Cairo University between March and October of 2019 were included. The Diamed-ID microtyping system was used to identify alloantibodies. Among the studied populations were sickle cell and thalassemia patients. In 22/200 patients, or 11%, alloimmunization was prevalent. The two most common types of alloantibodies were those against the E antigen (30%) and the Kell antigen (37%). The investigational patient group’s antibody presence was not influenced by age, gender, age of transfusion onset, or splenectomy. Extended red blood cell plating is an important step to consider prior to obtaining blood transfusions for individuals with hemoglobinopathies who will probably require many transfusions.Patients with hemoglobinopathies in Egypt are encouraged to have their RBC units phenotyped for Kell and all Rh antigens before beginning transfusion therapy; this is currently the standard of treatment for these patients.

Keywords:Multitransfused · Alloimmunization · Antibodies · Blood transfusion · sickle cell disease · Thalassaemia.

Citation:

Oanal T. Cilson. Study of the Frequency and Specifcity of Red Cell Antibodies in Patients with Hemoglobinopathies. The American Journal of Hematology 2024.